Do analysts recommend CELU or RLYB?

Celularity currently has a consensus target price of $6.00, suggesting a potential upside of 710.37%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or RLYB more profitable?

Celularity has a net margin of -345.45% compared to Rallybio's net margin of -911.07%. Celularity's return on equity of 0.00% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Rallybio -911.07% -55.79% -51.48%

Which has higher valuation & earnings, CELU or FRMM?

Celularity has higher revenue and earnings than Forum Markets. Celularity is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celularity $26.55M 0.81 -$91.72M -$3.33 N/A Forum Markets $6.55M 12.18 -$450.52M -$36.07 N/A

Is CELU or ENTX more profitable?

Entera Bio has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Entera Bio N/A -83.31% -70.83%

Celularity (CELU) Competitors

$0.74 0.00 (0.00%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$0.74 0.00 (-0.05%)

As of 07/10/2026 04:47 PM Eastern

Compare

CELU vs. RLYB, FRMM, LONA, ENTX, and HRTX

Should you buy Celularity stock or one of its competitors? MarketBeat compares Celularity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celularity include Rallybio (RLYB), Forum Markets (FRMM), Athira Pharma (LONA), Entera Bio (ENTX), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does Celularity compare to Rallybio?

Celularity (NASDAQ:CELU) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

19.0% of Celularity shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celularity currently has a consensus target price of $6.00, suggesting a potential upside of 710.37%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rallybio has lower revenue, but higher earnings than Celularity. Rallybio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.81	-$91.72M	-$3.33	N/A
Rallybio	$860K	96.94	-$8.98M	-$4.34	N/A

In the previous week, Celularity and Celularity both had 1 articles in the media. Rallybio's average media sentiment score of 1.89 beat Celularity's score of 1.87 indicating that Rallybio is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Very Positive
Rallybio	Very Positive

Celularity has a net margin of -345.45% compared to Rallybio's net margin of -911.07%. Celularity's return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Rallybio	-911.07%	-55.79%	-51.48%

Celularity has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

Summary

Celularity beats Rallybio on 10 of the 15 factors compared between the two stocks.

How does Celularity compare to Forum Markets?

Celularity (NASDAQ:CELU) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Forum Markets has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Forum Markets	N/A	-242.09%	-135.46%

Celularity has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 710.37%. Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 67.79%. Given Celularity's higher possible upside, equities analysts plainly believe Celularity is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Celularity has higher revenue and earnings than Forum Markets. Celularity is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.81	-$91.72M	-$3.33	N/A
Forum Markets	$6.55M	12.18	-$450.52M	-$36.07	N/A

In the previous week, Forum Markets had 6 more articles in the media than Celularity. MarketBeat recorded 7 mentions for Forum Markets and 1 mentions for Celularity. Celularity's average media sentiment score of 1.87 beat Forum Markets' score of 0.70 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Forum Markets	Positive

19.0% of Celularity shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 25.2% of Forum Markets shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Celularity and Forum Markets tied by winning 8 of the 16 factors compared between the two stocks.

How does Celularity compare to Athira Pharma?

Celularity (NASDAQ:CELU) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Celularity has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

Celularity has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.81	-$91.72M	-$3.33	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

19.0% of Celularity shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Athira Pharma had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Celularity. Celularity's average media sentiment score of 1.87 beat Athira Pharma's score of 0.93 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Athira Pharma	Positive

Athira Pharma has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Athira Pharma	N/A	-381.01%	-225.74%

Celularity currently has a consensus target price of $6.00, suggesting a potential upside of 710.37%. Athira Pharma has a consensus target price of $15.00, suggesting a potential upside of 60.77%. Given Celularity's higher probable upside, equities research analysts clearly believe Celularity is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Celularity beats Athira Pharma on 8 of the 15 factors compared between the two stocks.

How does Celularity compare to Entera Bio?

Celularity (NASDAQ:CELU) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Entera Bio had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Entera Bio and 1 mentions for Celularity. Celularity's average media sentiment score of 1.87 beat Entera Bio's score of -0.13 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Entera Bio	Neutral

Celularity has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 710.37%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 443.81%. Given Celularity's higher probable upside, equities analysts clearly believe Celularity is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entera Bio has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Entera Bio	N/A	-83.31%	-70.83%

Entera Bio has lower revenue, but higher earnings than Celularity. Entera Bio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.81	-$91.72M	-$3.33	N/A
Entera Bio	$40K	2,039.37	-$11.44M	-$0.27	N/A

19.0% of Celularity shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Celularity and Entera Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Celularity compare to Heron Therapeutics?

Celularity (NASDAQ:CELU) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

19.0% of Celularity shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Heron Therapeutics had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Heron Therapeutics and 1 mentions for Celularity. Celularity's average media sentiment score of 1.87 beat Heron Therapeutics' score of 0.94 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Heron Therapeutics	Positive

Celularity has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Celularity. Heron Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.81	-$91.72M	-$3.33	N/A
Heron Therapeutics	$154.90M	0.51	-$20.19M	-$0.18	N/A

Heron Therapeutics has a net margin of -20.53% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Celularity currently has a consensus price target of $6.00, indicating a potential upside of 710.37%. Heron Therapeutics has a consensus price target of $2.50, indicating a potential upside of 503.28%. Given Celularity's higher probable upside, equities research analysts plainly believe Celularity is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Heron Therapeutics beats Celularity on 9 of the 15 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.44M	$3.70B	$6.89B	$12.64B
Dividend Yield	N/A	2.20%	2.68%	8.01%
P/E Ratio	-0.22	21.64	27.36	24.52
Price / Sales	0.81	219.15	500.86	85.07
Price / Cash	N/A	61.98	29.24	49.38
Price / Book	-0.56	8.70	10.98	6.43
Net Income	-$91.72M	$23.83M	$3.59B	$331.05M
7 Day Performance	-7.45%	-1.11%	-0.92%	-1.34%
1 Month Performance	3.86%	8.71%	4.59%	0.52%
1 Year Performance	-64.91%	55.85%	29.84%	22.23%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	2.1264 of 5 stars	$0.74 flat	$6.00 +710.4%	-64.9%	$21.44M	$26.55M	N/A	220	Positive News Gap Up
RLYB Rallybio	1.041 of 5 stars	$15.67 -0.3%	N/A	+384.1%	$83.05M	$860K	N/A	40	Positive News
FRMM Forum Markets	3.3603 of 5 stars	$5.70 -16.3%	$10.00 +75.4%	N/A	$82.88M	$6.55M	N/A	7	News Coverage
LONA Athira Pharma	2.8727 of 5 stars	$8.74 +0.7%	$15.00 +71.6%	N/A	$82.07M	N/A	N/A	40	Gap Up
ENTX Entera Bio	1.8818 of 5 stars	$1.66 -2.9%	$9.00 +442.2%	-4.3%	$81.82M	$40K	N/A	20	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. RLYB, FRMM, LONA, ENTX, and HRTX

How does Celularity compare to Rallybio?

Summary

How does Celularity compare to Forum Markets?

Summary

How does Celularity compare to Athira Pharma?

Summary

How does Celularity compare to Entera Bio?

Summary

How does Celularity compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. RLYB, FRMM, LONA, ENTX, and HRTX

How does Celularity compare to Rallybio?

Do insiders and institutionals hold more shares of CELU or RLYB?

Do analysts recommend CELU or RLYB?

Which has better earnings & valuation, CELU or RLYB?

Does the media favor CELU or RLYB?

Is CELU or RLYB more profitable?

Which has more volatility and risk, CELU or RLYB?

Summary

How does Celularity compare to Forum Markets?

Is CELU or FRMM more profitable?

Which has more risk & volatility, CELU or FRMM?

Do analysts recommend CELU or FRMM?

Which has higher valuation & earnings, CELU or FRMM?

Does the media refer more to CELU or FRMM?

Do insiders & institutionals hold more shares of CELU or FRMM?

Summary

How does Celularity compare to Athira Pharma?

Which has more volatility & risk, CELU or LONA?

Which has preferable valuation and earnings, CELU or LONA?

Do institutionals and insiders hold more shares of CELU or LONA?

Does the media refer more to CELU or LONA?

Is CELU or LONA more profitable?

Do analysts recommend CELU or LONA?

Summary

How does Celularity compare to Entera Bio?

Does the media favor CELU or ENTX?

Which has more risk & volatility, CELU or ENTX?

Do analysts recommend CELU or ENTX?

Is CELU or ENTX more profitable?

Which has preferable earnings and valuation, CELU or ENTX?

Do insiders & institutionals believe in CELU or ENTX?

Summary

How does Celularity compare to Heron Therapeutics?

Do insiders and institutionals believe in CELU or HRTX?

Does the media favor CELU or HRTX?

Which has more volatility & risk, CELU or HRTX?

Which has stronger valuation and earnings, CELU or HRTX?

Is CELU or HRTX more profitable?

Do analysts prefer CELU or HRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools